Tuberculosis Epidemiology Forecast 2025-2034

Tuberculosis (TB) is an infectious disease caused by Mycobacterium tuberculosis. It is considered the leading cause of death from a single infectious agent. According to the World Health Organisation (WHO), around 10.8 million people worldwide were affected by tuberculosis in 2023 and about 1.25 million people died from the bacterial infection.

Tuberculosis Epidemiology Forecast Report Coverage

The “Tuberculosis Epidemiology Forecast Report 2025-2034” offers comprehensive information on the prevalence and demographics of tuberculosis. It projects the future incidence and prevalence rates of tuberculosis across various populations. The study covers age, gender, and type as major determinants of the tuberculosis-affected population. The report highlights patterns in the prevalence of tuberculosis over time and projects future trends based on multiple variables.

The report provides a comprehensive overview of the disease, as well as historical and projected data on the epidemiology of tuberculosis in the 8 major markets.

Regions Covered

• The United States
• Germany
• France
• Italy
• Spain
• The United Kingdom
• Japan
• India

Tuberculosis Disease Overview

Tuberculosis, also known as the white death, refers to a multisystem disease with various clinical manifestations. It usually affects the lungs and can spread to other parts of the body like the brain. Tuberculosis can be treated with antibiotics but can be fatal if left untreated. Common symptoms include fever, persistent cough, chest pain, coughing up blood and mucus, and fatigue, among others. In certain regions, infants and children are vaccinated with Bacille Calmette-Guérin (BCG) vaccine to protect them against tuberculosis infection.

Tuberculosis: Treatment Overview

The treatment for tuberculosis usually involves a combination of antibiotics which are taken over several months. First-line drugs include isoniazid (inhibits mycolic acid synthesis which is needed for bacterial cell walls), rifampin (suppresses bacterial RNA synthesis), pyrazinamide (targets semi-dormant bacteria), and ethambutol (inhibits bacterial cell wall formation). For drug-resistant tuberculosis, second-like drugs like linezolid, fluoroquinolones, and Bedaquiline are commonly prescribed for a period of 18 to 24 months.

Epidemiology

The tuberculosis epidemiology section offers information on the patient pool from history to the present as well as the projected trend for each of the 8 major markets. The publisher provides both current and predicted trends for tuberculosis by examining a wide range of studies. Additionally, the report covers the diagnosed patient pool for tuberculosis and their trends. The data is broken down into specific categories, such as total prevalent cases in males and females, and total diagnosed cases across different age groups and patient pools.

• In 2023, around 10.8 million people were affected by tuberculosis globally and 1.25 million died from the bacterial disease, according to the World Health Organisation (WHO).
• As per the Central TB Division, Ministry of Health and Family Welfare (India), approximately 10 million people are affected by tuberculosis annually, out of which nearly 3.2 million of the patient population is women.
• The Global TB Report 2022 estimated the incident cases of tuberculosis in 2021 to be 10.6 million.
• According to the Centers for Disease Control and Prevention (CDC), the 50 U.S. states and DC reported 9615 cases of tuberculosis in 2023, the highest number of cases reported since 2013.

Country-wise Tuberculosis Epidemiology

The tuberculosis epidemiology data and findings for the United States, EU-4 (Germany, Spain, Italy, France), the United Kingdom, Japan, and India are also provided in the epidemiology section.

The epidemiology of tuberculosis varies between countries due to several factors including access to treatment facilities, socioeconomic conditions, public health policies, HIV co-infection rates, and the prevalence of multidrug-resistant tuberculosis, among others. India is reported to have the world’s highest annual incidence of tuberculosis along with the highest tuberculosis-related mortality. According to a modeling study published in the Indian Journal of Community Medicine (2023), the incidence of tuberculosis was estimated to be 2.77 million in 2022 in the country.

Scope of the Report

• The report covers a detailed analysis of signs and symptoms, causes, risk factors, pathophysiology, diagnosis, treatment options, and classification/types of tuberculosis based on several factors.
• Tuberculosis Epidemiology Forecast Report covers data for the eight major markets (the US, France, Germany, Italy, Spain, the UK, Japan, and India).
• The report helps to identify the patient population and the unmet needs of tuberculosis are highlighted along with an assessment of the disease's risk and burden.

Key Questions Answered

• What are the key findings of tuberculosis epidemiology in the 8 major markets?
• What will be the total number of patients with tuberculosis across the 8 major markets during the forecast period?
• What was the country-wise prevalence of tuberculosis in the 8 major markets in the historical period?
• Which country will have the highest number of tuberculosis patients during the forecast period of 2025-2034?
• Which key factors would influence the shift in the patient population of tuberculosis during the forecast period of 2025-2034?
• What are the currently available treatments for tuberculosis?
• What are the disease risks, signs, symptoms, and unmet needs of tuberculosis?

This product will be delivered within 3-5 business days.